<DOC>
	<DOCNO>NCT01451268</DOCNO>
	<brief_summary>The study 's primary objective determine maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) Panobinostat administer within 150 day hematopoietic stem cell transplantation ( HSCT ) give conjunction standard immunosuppressive therapy HSCT patient high-risk Myelodysplastic Syndrome ( MDS ) Acute Myeloid Leukemia ( AML ) . Secondary objective - To determine safety tolerability panobinostat - To determine overall disease-free survival 12 month HSCT - To evaluate immunoregulatory property panobinostat - To evaluate patient-reported health-related quality life ( HRQL ) The hypothesis study panobinostat effective drug prevent relapse MDS AML patient high-risk feature hematopoietic stem cell transplantation reduced-intensity conditioning ( RIC-HSCT ) time reduce graft-versus-host disease ( GvHD ) preservation graft-versus-leukemia ( GvL ) effect .</brief_summary>
	<brief_title>Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation Patients With High Risk Myelodysplastic Syndrome ( MDS ) Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>AML ( except acute promyelocytic leukemia , AML M3 ) highrisk feature define one follow criterion : refractory relapse least one cycle standard chemotherapy &gt; 10 % bone marrow blast day 15 first induction cycle adverse risk cytogenetics include complex karyotype ( ≥ 3 abnormality abnormality chromosomes 3 , 5 7 ) regardless stage secondary MDS radio/chemotherapy MDS RAEB accord WHO classification intermediate2 highrisk accord IPSS Chronic myelomonocytic leukemia ( CMML ) ≥ 5 % bone marrow blast Allogeneic HSCT reduce intensity conditioning ( see Section 15.1 definition ) perform within 60 150 day prior study entry Complete hematologic remission document bone marrow aspiration within 28 day prior study entry Active acute GvHD overall grade 2 4 Prior treatment deacetylase ( DAC ) inhibitor Patients impaired cardiac function concurrent severe and/or uncontrolled medical condition Clinical symptom suggest central nervous system ( CNS ) leukemia Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral panobinostat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>60 150 Days After Allogeneic Stem Cell Transplantation</keyword>
	<keyword>High Risk MDS</keyword>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
</DOC>